Inflammatory Cytokine: IL-17A Signaling Pathway in Patients Present with COVID-19 and Current Treatment Strategy

References

• Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–733. doi:10.1056/NEJMoa200101731978945
   PubMed Web of Science ®Google Scholar
• Xu C, Luo X, Yu C, Cao S-J. The 2019-nCoV epidemic control strategies and future challenges of building healthy smart cities. Indoor and Built Environment. 2020;29(5):639–644. doi:10.1177/1420326X20910408
   Web of Science ®Google Scholar
• Rothe C, Schunk M, Sothmann P, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med. 2020;382(10):970–971. doi:10.1056/NEJMc200146832003551
   PubMed Web of Science ®Google Scholar
• World Health Organization. Coronavirus disease (COVID-19): situation report. 2019.
   Google Scholar
• Chen Y, Liu Q, Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol. 2020. doi:10.1002/jmv.26234
   Web of Science ®Google Scholar
• Chen J. Pathogenicity and transmissibility of 2019-nCoV—A quick overview and comparison with other emerging viruses. Microbes Infect. 2020;22(2):69–71. doi:10.1016/j.micinf.2020.01.00432032682
   PubMed Web of Science ®Google Scholar
• Benvenuto D, Giovannetti M, Ciccozzi A, Spoto S, Angeletti S, Ciccozzi M. The 2019‐new coronavirus epidemic: evidence for virus evolution. J Med Virol. 2020;92(4):455–459. doi:10.1002/jmv.2568831994738
   PubMed Web of Science ®Google Scholar
• Hotez PJ, Bottazzi ME, Corry DB. The Potential Role of TH17 Immune Responses in Coronavirus Immunopathology and Vaccine-Induced Immune Enhancement. Elsevier; 2020.
   Google Scholar
• Zhang W, Zhao Y, Zhang F, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the experience of clinical immunologists from China. Clin Immunol. 2020;214:108393. doi:10.1016/j.clim.2020.10839332222466
   PubMed Web of Science ®Google Scholar
• Jin W, Dong C. IL-17 cytokines in immunity and inflammation. Emerg Microbes Infect. 2013;2(1):1–5. doi:10.1038/emi.2013.58
   PubMed Web of Science ®Google Scholar
• Bulat V, Situm M, Azdajic MD, Likic R. Potential role of IL‐17 blocking agents in the treatment of severe COVID‐19? Br J Clin Pharmacol. 2020. doi:10.1111/bcp.14437
   Web of Science ®Google Scholar
• Mahallawi WH, Khabour OF, Zhang Q, Makhdoum HM, Suliman BA. MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile. Cytokine. 2018;104:8–13. doi:10.1016/j.cyto.2018.01.02529414327
   PubMed Web of Science ®Google Scholar
• Righetti RF, Santos TMD, Camargo LDN, et al. Protective effects of anti-IL17 on acute lung injury induced by LPS in mice. Front Pharmacol. 2018;9:1021. doi:10.3389/fphar.2018.0102130337870
   PubMedGoogle Scholar
• Wu D, Yang XO. TH17 responses in cytokine storm of COVID-19: an emerging target of JAK2 inhibitor Fedratinib. J Microbiol Immunol Infect. 2020;53(3):368–370. doi:10.1016/j.jmii.2020.03.00532205092
   PubMedGoogle Scholar
• Du F, Liu B, Zhang S. COVID-19: the role of excessive cytokine release and potential ACE2 down-regulation in promoting hypercoagulable state associated with severe illness. J Thromb Thrombolysis. 2020;1–17.
   Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi:10.1016/S0140-6736(20)30183-531986264
   PubMed Web of Science ®Google Scholar
• Girija A, Shankar EM, Larsson M. Could SARS-CoV-2-induced hyperinflammation magnify the severity of coronavirus disease (CoViD-19) leading to acute respiratory distress syndrome? Front Immunol. 2020;11:1206. doi:10.3389/fimmu.2020.0120632574269
   PubMed Web of Science ®Google Scholar
• Faure E, Poissy J, Goffard A, et al. Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside? PLoS One. 2014;9(2):e88716. doi:10.1371/journal.pone.008871624551142
   PubMed Web of Science ®Google Scholar
• Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet. 2020;395(10223):470–473. doi:10.1016/S0140-6736(20)30185-931986257
   PubMed Web of Science ®Google Scholar
• Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020.
   PubMed Web of Science ®Google Scholar
• Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med. 2020;8(6):e46–e47. doi:10.1016/S2213-2600(20)30216-232353251
   PubMed Web of Science ®Google Scholar
• Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China. Clin Infect Dis. 2020. doi:10.1093/cid/ciaa538
   Web of Science ®Google Scholar
• Fang Y, Zhang H, Xu Y, Xie J, Pang P, Ji W. CT manifestations of two cases of 2019 novel coronavirus (2019-nCoV) pneumonia. Radiology. 2020;295(1):208–209. doi:10.1148/radiol.202020028032031481
   PubMed Web of Science ®Google Scholar
• Xu J, Zhao S, Teng T, et al. Systematic comparison of two animal-to-human transmitted human coronaviruses: SARS-CoV-2 and SARS-CoV. Viruses. 2020;12(2):244. doi:10.3390/v12020244
   PubMed Web of Science ®Google Scholar
• Diao B, Wang C, Tan Y, et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front Immunol. 2020;11:827. doi:10.3389/fimmu.2020.0082732425950
   PubMed Web of Science ®Google Scholar
• Su S, Wong G, Shi W, et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol. 2016;24(6):490–502. doi:10.1016/j.tim.2016.03.00327012512
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li J, Zhan Y, et al. Analysis of serum cytokines in patients with severe acute respiratory syndrome. Infect Immun. 2004;72(8):4410–4415. doi:10.1128/IAI.72.8.4410-4415.200415271897
   PubMed Web of Science ®Google Scholar
• Jiang Y, Xu J, Zhou C, et al. Characterization of cytokine/chemokine profiles of severe acute respiratory syndrome. Am J Respir Crit Care Med. 2005;171(8):850–857. doi:10.1164/rccm.200407-857OC15657466
   PubMed Web of Science ®Google Scholar
• Quirch M, Lee J, Rehman S. Hazards of the cytokine storm and cytokine-targeted therapy in patients with COVID-19. J Med Internet Res. 2020;22(8):e20193. doi:10.2196/2019332707537
   PubMed Web of Science ®Google Scholar
• Llosa NJ, Geis AL, Orberg ET, Housseau F. Interleukin-17 and type 17 helper T cells in cancer management and research. ImmunoTargets Ther. 2014;3:39.27471699
   PubMedGoogle Scholar
• Tesmer LA, Lundy SK, Sarkar S, Fox DA. Th17 cells in human disease. Immunol Rev. 2008;223(1):87–113.18613831
   PubMed Web of Science ®Google Scholar
• McGeachy MJ, Cua DJ. Th17 cell differentiation: the long and winding road. Immunity. 2008;28(4):445–453. doi:10.1016/j.immuni.2008.03.00118400187
   PubMed Web of Science ®Google Scholar
• Sekine T, Perez-Potti A, Rivera-Ballesteros O, et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell. 2020. doi:10.1016/j.cell.2020.08.017
   Web of Science ®Google Scholar
• Pacha O, Sallman MA, Evans SE. COVID-19: a case for inhibiting IL-17? Nat Rev Immunol. 2020;20(6):345–346. doi:10.1038/s41577-020-0328-z32358580
   PubMed Web of Science ®Google Scholar
• Ghilardi N, Ouyang W Targeting the development and effector functions of TH17 cells. Paper presented at: Seminars in immunology. 2007; 19(6):383–393. Academic Press.
   Google Scholar
• Ivanov II, McKenzie BS, Zhou L, et al. The orphan nuclear receptor RORγt directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell. 2006;126(6):1121–1133. doi:10.1016/j.cell.2006.07.03516990136
   PubMed Web of Science ®Google Scholar
• Raucci F, Mansour AA, Casillo GM, et al. Interleukin-17A (IL-17A), a key molecule of innate and adaptive immunity, and its potential involvement in COVID-19-related thrombotic and vascular mechanisms. Autoimmun Rev. 2020;19(7):102572. doi:10.1016/j.autrev.2020.10257232376393
   PubMed Web of Science ®Google Scholar
• Bunte K, Beikler T. Th17 cells and the IL-23/IL-17 axis in the pathogenesis of periodontitis and immune-mediated inflammatory diseases. Int J Mol Sci. 2019;20(14):3394. doi:10.3390/ijms20143394
   PubMed Web of Science ®Google Scholar
• Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420–422. doi:10.1016/S2213-2600(20)30076-X32085846
   PubMed Web of Science ®Google Scholar
• Josset L, Menachery VD, Gralinski LE, et al. Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus. MBio. 2013;4:3. doi:10.1128/mBio.00165-13
   Web of Science ®Google Scholar
• Tan L, Wang Q, Zhang D, et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduct Target Ther. 2020;5(1):1–3.32296011
   PubMed Web of Science ®Google Scholar
• Bermejo-Martin JF, Almansa R, Menéndez R, Mendez R, Kelvin DJ, Torres A. Lymphopenic community acquired pneumonia as signature of severe COVID-19 infection. J Infect. 2020;80(5):e23. doi:10.1016/j.jinf.2020.02.02932145214
   PubMed Web of Science ®Google Scholar
• Cafarotti S. Severe acute respiratory syndrome–Coronavirus-2 Infection and patients with lung cancer: the potential role of interleukin-17 target therapy. J Thorac Oncol. 2020;15(7):e101–e103. doi:10.1016/j.jtho.2020.04.01532353597
   PubMed Web of Science ®Google Scholar
• Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020.
   Web of Science ®Google Scholar
• Yajing F, Cheng Y, Wu Y. Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools. Virol Sin. 2020;6.
   Google Scholar
• Ma W-T, Yao X-T, Peng Q, Chen D-K. The protective and pathogenic roles of IL-17 in viral infections: friend or foe? Open Biol. 2019;9(7):190109. doi:10.1098/rsob.19010931337278
   PubMed Web of Science ®Google Scholar
• Veldhoen M. Interleukin 17 is a chief orchestrator of immunity. Nat Immunol. 2017;18(6):612. doi:10.1038/ni.374228518156
   PubMed Web of Science ®Google Scholar
• Badawi A. Hypercytokinemia and pathogen–host interaction in COVID-19. J Inflamm Res. 2020;13:255. doi:10.2147/JIR.S25909632606886
   PubMed Web of Science ®Google Scholar
• Ryzhakov G, Lai CC-K, Blazek K, To K-W, Hussell T, Udalova I. IL-17 boosts proinflammatory outcome of antiviral response in human cells. J Immunol. 2011;187(10):5357–5362. doi:10.4049/jimmunol.110091721964025
   PubMed Web of Science ®Google Scholar
• Guglani L, Khader SA. Th17 cytokines in mucosal immunity and inflammation. Curr Opin HIV AIDS. 2010;5(2):120. doi:10.1097/COH.0b013e328335c2f620543588
   PubMed Web of Science ®Google Scholar
• Onishi RM, Gaffen SL. Interleukin‐17 and its target genes: mechanisms of interleukin‐17 function in disease. Immunology. 2010;129(3):311–321.20409152
   PubMed Web of Science ®Google Scholar
• Brembilla NC, Senra L, Boehncke W-H. The IL-17 family of cytokines in psoriasis: IL-17A and beyond. Front Immunol. 2018;9:1682. doi:10.3389/fimmu.2018.0168230127781
   PubMed Web of Science ®Google Scholar
• Frieman M, Heise M, Baric R. SARS coronavirus and innate immunity. Virus Res. 2008;133(1):101–112. doi:10.1016/j.virusres.2007.03.01517451827
   PubMed Web of Science ®Google Scholar
• Satija N, Lal SK. The molecular biology of SARS coronavirus. Ann N Y Acad Sci. 2007;1102(1):26–38. doi:10.1196/annals.1408.00217470909
   PubMed Web of Science ®Google Scholar
• Calabrese LH. Cytokine storm and the prospects for immunotherapy with COVID-19. Cleve Clin J Med. 2020.
   Web of Science ®Google Scholar
• Organization WH. Clinical Management of Severe Acute Respiratory Infection (SARI) When COVID-19 Disease is Suspected: Interim Guidance, 13 March 2020. World Health Organization; 2020.
   Google Scholar
• Quartuccio L, Semerano L, Benucci M, Boissier M-C, De Vita S. Urgent avenues in the treatment of COVID-19: targeting downstream inflammation to prevent catastrophic syndrome. Joint Bone Spine. 2020;87(3):191. doi:10.1016/j.jbspin.2020.03.01132321634
   PubMed Web of Science ®Google Scholar
• Ritchlin CT, Krueger JG. New therapies for psoriasis and psoriatic arthritis. Curr Opin Rheumatol. 2016;28(3):204. doi:10.1097/BOR.000000000000027427022911
   PubMed Web of Science ®Google Scholar
• Fletcher JM, Moran B, Petrasca A, Smith CM. IL‐17 in inflammatory skin diseases psoriasis and hidradenitis suppurativa. Clin Exp Immunol. 2020;201(2):121–134. doi:10.1111/cei.1344932379344
   PubMed Web of Science ®Google Scholar
• Truchetet M-E, Mossalayi MD, Boniface K. IL-17 in the rheumatologist’s line of sight. Biomed Res Int. 2013;2013:1–18. doi:10.1155/2013/295132
   Web of Science ®Google Scholar
• Robak E, Gerlicz-Kowalczuk Z, Dziankowska-Bartkowiak B, Wozniacka A, Bogaczewicz J. Serum concentrations of IL-17A, IL-17B, IL-17E and IL-17F in patients with systemic sclerosis. Arch Med Sci. 2019;15(3):706. doi:10.5114/aoms.2019.8473831110538
   PubMed Web of Science ®Google Scholar
• Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020;368(6490):473–474. doi:10.1126/science.abb892532303591
   PubMed Web of Science ®Google Scholar
• Georgiev T. Coronavirus disease 2019 (COVID-19) and anti-rheumatic drugs. Rheumatol Int. 2020;1.
   Google Scholar
• Abdin SM, Elgendy SM, Alyammahi SK, Alhamad DW, Omar HA. Tackling the cytokine storm in COVID-19, challenges, and hopes. Life Sci. 2020;257:118054. doi:10.1016/j.lfs.2020.11805432663575
   PubMed Web of Science ®Google Scholar
• Favalli EG, Biggioggero M, Maioli G, Caporali R. Baricitinib for COVID-19: a suitable treatment? Lancet Infect Dis. 2020;20(9):1012–1013. doi:10.1016/S1473-3099(20)30262-0
   PubMed Web of Science ®Google Scholar
• Zhong J, Tang J, Ye C, Dong L. The immunology of COVID-19: is immune modulation an option for treatment? Lancet Rheumatol. 2020;2(7):e428–e436. doi:10.1016/S2665-9913(20)30120-X32835246
   PubMedGoogle Scholar